The findings place p38β at the center of a biological switch that allows liver cancer cells to preserve stem-like properties while avoiding a cellular alarm system known as the unfolded protein response, or UPR. Cancer cells often manufacture unusually large amounts of proteins, remodel their metabolism and endure oxygen deprivation, creating intense stress inside the endoplasmic reticulum, the cellular compartment responsible for folding and processing newly made proteins. Under normal circumstances, this stress activates the UPR, which either restores protein-folding capacity or, if damage is too severe, triggers programmed cell death.

BiP, also known as HSPA5 or GRP78, is one of the UPR’s key regulators. It acts as a molecular chaperone, helping proteins fold correctly and monitoring stress-sensing pathways embedded in the endoplasmic-reticulum membrane. When unfolded proteins accumulate, BiP changes its interactions with these sensors, including PERK, IRE1 and ATF6, initiating a coordinated response. This response can temporarily protect a cell, but persistent or excessive UPR activation may become lethal. The new research indicates that p38β-mediated phosphorylation changes BiP’s behavior in a way that dampens this protective checkpoint.

Phosphorylation is a reversible chemical modification in which a phosphate group is attached to a protein, often altering its shape, stability, location or interactions with other molecules. Protein kinases such as p38β perform this modification in response to intracellular signals, including inflammation, oxidative stress and other forms of environmental pressure. According to the study, p38β targets BiP and thereby suppresses UPR activation in hepatocellular carcinoma cells. Rather than allowing endoplasmic-reticulum stress to escalate toward cell death, the modified BiP appears to help malignant cells maintain a state of controlled adaptation.

That adaptation may be particularly important for cancer stemness. Cancer stem-like cells are not necessarily identical to normal tissue stem cells, but they share properties such as self-renewal, developmental flexibility and the ability to generate diverse tumor-cell populations. In liver cancer, these cells are widely considered a major source of tumor initiation, recurrence and treatment resistance. By sustaining stemness-associated programs, the p38β–BiP pathway could help a small fraction of tumor cells survive therapy and later repopulate the tumor.

The mechanism also offers an explanation for chemoresistance. Many anticancer drugs damage DNA, disrupt replication or intensify metabolic and protein-folding stress. A cancer cell that can suppress the UPR’s lethal consequences may tolerate these pressures more effectively than a less adaptable cell. The study’s central conclusion is that p38β-dependent BiP phosphorylation provides hepatocellular carcinoma with precisely this advantage, allowing tumor cells to withstand treatment while preserving the biological traits linked to relapse.

The work is significant because it connects three processes that are often studied separately: stress signaling, cancer-cell plasticity and drug resistance. p38 kinases have long been associated with inflammatory and stress responses, while BiP has been examined as a marker and regulator of endoplasmic-reticulum stress. Linking a specific kinase-driven modification of BiP to stemness and chemotherapy resistance suggests that the interaction is not merely a consequence of tumor stress, but may actively organize the cancer cell’s survival strategy.

The findings also point toward a potential therapeutic vulnerability. In principle, blocking p38β activity, preventing BiP phosphorylation or restoring an appropriate UPR response could make tumor cells less able to tolerate chemotherapy. Such strategies would require careful development, however. The p38 family participates in normal immune, inflammatory and tissue-repair processes, while BiP is essential for healthy cells that experience physiological protein-folding demands. A treatment that interferes with this pathway would need to distinguish malignant stress adaptation from normal cellular maintenance.

Future studies will be needed to determine how broadly the mechanism operates across patient tumors, whether BiP phosphorylation can be measured reliably as a biomarker and which treatment combinations are most effective. It will also be important to establish whether p38β inhibition can selectively eliminate stem-like cancer cells without causing unacceptable toxicity. Nevertheless, the study offers a compelling molecular explanation for why some liver tumors remain stubbornly resistant: they may be using a kinase-controlled modification of a central stress chaperone to keep their internal alarm system quiet while preserving the capacity to survive, renew and return.

Subject of Research: p38β-mediated BiP phosphorylation, unfolded protein response suppression, stemness and chemoresistance in hepatocellular carcinoma

Article Title: p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma

Article References: Xu, L., Huang, I.B., Zhang, M. et al. p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76073-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76073-7

Keywords: hepatocellular carcinoma, liver cancer, p38β, BiP, HSPA5, GRP78, phosphorylation, unfolded protein response, endoplasmic reticulum stress, cancer stemness, chemoresistance, cancer biology

In breast cancer, distinct subtypes display notable heterogeneity in ERS response. Estrogen receptor-positive (ER+) tumors often tolerate moderate ERS activation, which facilitates cellular adaptation. However, persistent ERS provokes apoptosis through intricate mitochondria-endoplasmic reticulum calcium signaling and reactive oxygen species (ROS) accumulation. Conversely, triple-negative breast cancers endure heightened baseline ERS, making them susceptible yet simultaneously adept at developing resistance via anti-apoptotic proteins such as FLIP. This dualistic nature exemplifies the balancing act cancer cells perform between survival and death, underscoring the challenge of exploiting ERS pathways therapeutically.

Within the complex tumor microenvironment, stressors like hypoxia, acidity, and nutrient scarcity act as relentless triggers for the unfolded protein response (UPR), perpetuating ERS signaling. ERS reciprocally remodels the microenvironment, simultaneously enhancing anti-tumor immunity by inducing immunogenic cell death (ICD) through modalities such as calreticulin exposition and HMGB1 release, while also promoting immunosuppression via mechanisms including PD-L1 glycosylation. Notably, ERS-mediated exosomal microRNAs, like miR-27a-3p, modulate macrophage immune checkpoint expression via molecular cascades, revealing sophisticated tumor immune escape strategies embedded within ERS signaling frameworks.

Colorectal cancer’s interplay between ERS and various cell death modalities underscores a nuanced regulatory landscape. The ferroptosis inducer RSL3 activates all UPR arms, with the PERK pathway dampening ferroptosis by modulating transcriptional regulation of critical cystine-glutamate antiporter components. This interplay suggests that modulating ERS pathways could overcome traditional apoptosis resistance, opening new therapeutic horizons. Moreover, dual induction of ferroptosis and ICD by agents like macrocarpal I enhances the efficacy of immune checkpoint blockade, highlighting the benefit of temporally calibrated ERS manipulation.

Hepatocellular carcinoma (HCC) demonstrates how ERS signaling pathways intertwine with diverse cell death forms to dictate tumor behavior and therapeutic outcome. Natural compounds, such as Icaritin and Fisetin, leverage ERS activation to induce mitochondrial dysfunction and calcium disruption, amplifying apoptotic pathways. Under therapeutic stress, ERS-induced autophagy serves as a protective shield against apoptosis, contributing to sorafenib resistance. Interventions that modulate this crosstalk, including melatonin’s inhibition of protective autophagy, reinstate drug sensitivity. Furthermore, ERS elements also govern metastatic potential by fostering anoikis resistance, indicating these pathways’ role extends beyond cell death into tumor dissemination.

Glioblastoma multiforme (GBM) epitomizes the challenges of therapy resistance linked to ERS/UPR dysregulation. Compounds such as sulforaphane induce ATF4–CHOP mediated apoptosis, whereas proteasome inhibitors, like marizomib, trigger caspase-dependent cell death independent of ROS or autophagy pathways. Intriguingly, remdesivir exhibits superior antitumor efficacy via PERK-orchestrated UPR, hinting at repurposed antiviral agents’ potential in oncology. The heterogenous ERS response in therapy-resistant GBM subtypes highlights the complexity of the tumor’s adaptive machinery and emphasizes the need for combination strategies targeting multiple ERS nodes.

Lung cancer progression and immune evasion are intimately linked with ERS-induced modulation of the tumor milieu. The oxidoreductase ERO1A shapes immunosuppressive environments by balancing IRE1α and PERK pathways and its inhibition potentiates PD-1 blockade responses. Other modulators like Derlin-3 drive macrophage polarization, reinforcing immune escape. Photodynamic therapies exploit ROS to instigate ERS and DNA damage, bolstering tumor immunogenicity. Furthermore, ERS-related gene signatures serve as prognostic indicators, with high-risk groups exhibiting blunted immune infiltration and attenuated treatment responses, illuminating the translational relevance of ERS biomarkers.

In pancreatic ductal adenocarcinoma (PDAC), ERS is a double-edged sword that propels tumor progression and resistance. Single-cell analyses have spotlighted tumor-associated neutrophil subsets with glycolytic profiles governed by ERS-associated transcription factors, fostering immunosuppression via chemokine secretion and checkpoint regulation. The molecular crosstalk where RUNX1 activates BiP/PERK/eIF2α signaling reinforces chemoresistance, which can be reversed pharmacologically. Nanotechnology-based delivery systems simultaneously targeting ERS pathways and immune checkpoints exemplify the frontiers of therapeutic innovation in this notoriously resistive cancer type.

Natural products across cancer types consistently emerge as potent ERS modulators to induce tumor cell death. Tocotrienols and oleandrin in breast cancer, curcumin and gambogenic acid in colorectal cancer, and secoemestrin C in PDAC exemplify the therapeutic potential harnessed from bioactive compounds targeting ERS-death axes. These agents engender ERS-mediated apoptosis through canonical pathways such as PERK-eIF2α-ATF4-CHOP or induce irreversible proteostasis collapse, thus overcoming conventional drug resistance mechanisms.

Therapeutic resistance often pivots on dynamic ERS responses where the equilibrium between death and survival signals is delicately tuned. For instance, sorafenib’s induction of protective autophagy via the PERK-ATF4-Beclin1 cascade in HCC demonstrates how a cytoprotective mechanism can complicate treatment outcomes. Agents that disrupt these survival cues restore apoptotic sensitivity, a principle echoed across tumor models. Similarly, in GBM, proteasomal activity modulates ERS and autophagy interplay, influencing temozolomide resistance, and targeting these pathways enhances therapeutic efficacy.

The tumor microenvironment reprogrammed by ERS influences metastatic progression and immune landscape remodeling. In HCC, ERS-adaptive proteins enhance anoikis resistance, promoting metastasis correlating with clinical metrics such as tumor size and stage. ERS-driven immunosuppressive signaling axes, like MIF/CD74+CXCR4, underscore how tumors manipulate local immunity to their advantage. Interventions that modulate ERS can shift this balance, restoring immune surveillance and dampening metastatic propensity.

Emerging therapies targeting the ERS machinery demonstrate profound potential in enhancing cancer treatment. Combinations such as PERK agonists with taxanes or proteasome inhibitors paired with ERS inhibitors unleash synergistic apoptotic responses. Novel targeted agents, including UBA1 and GRP78 inhibitors, induce irreversible UPR tipping cancer cells beyond their adaptive capacity. Nanoformulations augment delivery and efficacy of ERS modulators, underscoring the importance of technological advances in translating these molecular insights into clinical reality.

Metabolic reprogramming intimately intersects with ERS regulation, bridging cellular stress and tumor survival. Lung and pancreatic cancers exhibit metabolic alterations that integrate with ERS signaling to confer adaptive advantages. The PERK pathway, via modulators like BZW1 and PPARγ ligands, orchestrates glycolysis and ROS balance, influencing cell fate decisions under metabolic duress. Targeting these metabolic-ERS nodes disrupts tumor resilience, providing a multifaceted approach to combat resistant malignancies.

Within glioblastoma, the tumor’s subpopulation heterogeneity reveals distinct ERS dependencies that correlate with treatment sensitivity and recurrence. Strategies disrupting protein ubiquitination and folding, such as the UBA1 inhibitor TAK-243, combined with GRP78 antagonists, demonstrate remarkable potential in overcoming GBM robustness. Moreover, metabolic interventions harnessing ERS-mitochondrial crosstalk exploit vulnerabilities in glioma stem cells, emphasizing the crucial role of integrated stress responses in tumor eradication.

The immunogenic potential of ERS-induced cell death is increasingly recognized as a critical component in orchestrating effective antitumor immunity. Agents that trigger ICD, including several natural and synthetic compounds, not only kill cancer cells but also prime immune responses by exposing damage-associated molecular patterns. This dual function advocates for ERS-targeted therapies in combination with immunotherapies, aiming to dismantle immune evasion mechanisms entrenched within tumor microenvironments across cancer types.

The intricate nexus between ERS, programmed cell death, and the tumor microenvironment emerges as a fertile landscape for transformative cancer therapies. As the molecular choreography underlying ERS signaling pathways continues to unfold, it paves the way for innovative interventions that can finely tune this balance, circumvent resistance, and mobilize anti-tumor immunity. The future of oncology lies in decoding and manipulating this multifaceted axis to achieve durable clinical successes.

Subject of Research: Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment

Article Title: Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment

Article References:
Chai, H., Hu, Q., Yao, S. et al. Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment. Cell Death Discov. 11, 559 (2025). https://doi.org/10.1038/s41420-025-02862-6

Image Credits: AI Generated

DOI: 17 December 2025

Non-small cell lung cancer remains a leading cause of cancer mortality worldwide, with treatment efficacy often hampered by the tumor’s ability to develop resistance to frontline chemotherapeutic agents like cisplatin. The hypoxic microenvironment, a hallmark of solid tumors including NSCLC, imposes a significant influence on cellular metabolic and survival pathways. While the cellular adaptation to low oxygen levels has been extensively studied, the precise molecular interplay by which hypoxia facilitates autophagy-driven chemoresistance has remained obscure—until now.

The study dives into the complex cellular stress response triggered under hypoxia, revealing that autophagy—a self-degradative process that recycles cellular components—is not merely a survival mechanism but a pivotal modulator of cisplatin resistance. The research team identified EIF2AK3, also known as PERK, a crucial sensor of endoplasmic reticulum stress, as a key upstream regulator that activates PI3K/AKT signaling under hypoxic conditions. This cascade fortifies cancer cells against cisplatin-induced apoptosis, illustrating an adaptive survival circuit finely tuned by the hypoxic tumor niche.

Crucially, this pathway exerts its effects independently of the mechanistic target of rapamycin (mTOR), which traditionally governs cellular growth and autophagy regulation. This mTOR-independent mechanism challenges prevailing paradigms and suggests that alternative autophagy control routes may sustain tumor cell survival in chemotherapy-treated hypoxic environments. Such insights spotlight potential pitfalls of solely targeting mTOR signaling in therapeutic regimens and underscore the necessity for broader pathway exploration.

Detailed molecular analyses showed that activation of EIF2AK3 under hypoxic stress leads to the phosphorylation and activation of downstream PI3K/AKT components, enhancing autophagic flux without engaging mTOR. This mechanism sustains crucial metabolic homeostasis and prevents apoptosis induced by cisplatin, contributing to a robust resistance phenotype that is notoriously difficult to reverse. The researchers validated these findings through in vitro and in vivo models, demonstrating marked decreases in tumor responsiveness to cisplatin upon activation of this axis.

Importantly, pharmacological inhibition of EIF2AK3 disrupted the downstream PI3K/AKT signaling and significantly attenuated autophagy, sensitizing NSCLC cells to cisplatin-induced death. This revelation propounds EIF2AK3 not just as a biomarker of hypoxia-driven resistance but also as a compelling therapeutic target. The prospect of developing EIF2AK3 inhibitors or dual-targeting agents presents an exciting avenue to circumvent chemoresistance and improve patient outcomes.

The study’s approach is notable for integrating advanced molecular biology techniques with functional assays to dissect the temporal dynamics of hypoxia-induced autophagy. This holistic methodology provided a comprehensive portrait of the adaptive strategies employed by NSCLC cells, highlighting the sophisticated interplay between environmental stressors and intracellular signaling networks.

Furthermore, the research underscores the heterogeneity within NSCLC tumors, where different cellular subpopulations may exploit distinct survival pathways. This variability mandates precision medicine strategies tailored to the dominant resistance mechanisms operative in individual tumors. The EIF2AK3-dependent PI3K/AKT signaling axis emerges as a significant determinant in this landscape, advocating for its inclusion in molecular profiling panels.

In the broader context of cancer biology, these findings resonate with accumulating data implicating hypoxia and autophagy in therapy resistance across multiple malignancies. They reinforce a paradigm shift where autophagy modulation is no longer viewed as a binary pro-survival or pro-death process but as a nuanced, context-dependent phenomenon that can be manipulated for therapeutic benefit.

The implications extend to combination therapy design, where inhibitors targeting the EIF2AK3-PI3K/AKT pathway could be synergized with cisplatin or other chemotherapeutics. Such strategies might rescue drug responsiveness in resistant tumors, potentially translating into prolonged survival and better quality of life for patients.

This paradigm-challenging research also prompts a reevaluation of clinical trial designs, encouraging incorporation of hypoxia and autophagy biomarkers to stratify patients more effectively and tailor interventions that preempt the development of resistance. The integration of these molecular insights into clinical oncology heralds an era of more intelligent, mechanism-driven treatment protocols.

Looking ahead, further elucidation of downstream effectors within the EIF2AK3-PI3K/AKT pathway and their crosstalk with other survival networks may unveil additional targets to amplify therapeutic efficacy. Moreover, understanding how tumor microenvironmental factors intersect with genetic and epigenetic alterations in NSCLC will be critical to refine these novel treatment avenues.

By deciphering the mTOR-independent autophagy mechanisms underpinning hypoxia-induced cisplatin resistance, this study provides a vital conceptual framework for future interventions. It empowers the scientific community with actionable targets that could hinder the cellular escape routes cancer cells exploit to evade chemotherapy cytotoxicity.

In essence, the convergence of hypoxia, autophagy, and EIF2AK3-driven signaling sketches a sophisticated survival blueprint for NSCLC cells. Interrupting this blueprint holds promise to dismantle tumor resilience and revive the potency of existing chemotherapeutic arsenals, making this a landmark contribution to the ongoing battle against lung cancer.

As we translate these laboratory discoveries into clinical realities, the hope is that such insights will spawn next-generation treatments that are not only more effective but also tailored to the complex interplay of tumor biology and microenvironmental stress, ultimately transforming patient care paradigms in NSCLC.

Subject of Research: Mechanisms of hypoxia-induced autophagy modulating cisplatin resistance in non-small cell lung cancer via EIF2AK3-dependent signaling.

Article Title: Hypoxia-triggered autophagy modulates cisplatin resistance in non-small cell lung cancer via EIF2AK3-dependent PI3K/AKT signaling and mTOR-independent mechanisms.

Article References:
Fu, J., Xu, W., Wang, G. et al. Hypoxia-triggered autophagy modulates cisplatin resistance in non-small cell lung cancer via EIF2AK3-dependent PI3K/AKT signaling and mTOR-independent mechanisms. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02893-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02893-z

Cold atmospheric plasma has emerged as a promising anti-cancer tool due to its ability to generate reactive oxygen and nitrogen species that induce oxidative stress and cell death selectively in tumor cells. However, the efficacy of CAP treatment can be markedly influenced by the surrounding cellular milieu within the tumor, particularly immune cells such as macrophages. Macrophages are highly plastic immune cells capable of adopting distinct functional phenotypes in response to environmental cues. The M2 macrophage phenotype is generally associated with immunosuppressive, tissue remodeling, and tumor-promoting properties.

The new research reveals that M2 polarized macrophages confer a protective advantage to lung cancer cells exposed to CAP by alleviating endoplasmic reticulum (ER) stress, a critical driver of CAP-induced cytotoxicity. ER stress involves the accumulation of misfolded proteins within the ER lumen, triggering a cellular response known as the unfolded protein response (UPR). While prolonged ER stress leads to apoptosis, mitigating ER stress can enhance cancer cell survival under treatment-induced stress conditions.

Through a series of meticulous in vitro and in vivo experiments, the study demonstrates that conditioned media from M2 polarized macrophages significantly reduce markers of ER stress in lung cancer cells following CAP exposure. This reduction in ER stress corresponded with decreased apoptotic cell death and enhanced cell viability, highlighting a direct protective effect imparted by the macrophages. Conversely, M1 polarized macrophages—typically pro-inflammatory and anti-tumorigenic—did not exhibit this protective effect, underscoring the specificity of the M2 phenotype in promoting cancer cell resistance to CAP.

At the molecular level, the researchers identified key signaling pathways involved in this protective mechanism. The M2 macrophages secreted factors that modulated the PERK-eIF2α-ATF4 axis, a fundamental UPR pathway regulating ER stress responses. By attenuating the activation of PERK and downstream effectors, the macrophage-conditioned media effectively dampened the pro-apoptotic signals induced by CAP. This intricate crosstalk provides new insight into how tumor-associated macrophages can subvert therapeutic pressure by rewiring stress responses within cancer cells.

Importantly, these findings have significant implications for the clinical application of CAP in oncology. Lung cancers that possess a high infiltration of M2 polarized macrophages may exhibit intrinsic resistance to CAP therapy, necessitating combination strategies that target both cancer cells and their supportive immune microenvironment. Potential therapeutic approaches could involve reprogramming macrophage polarization from the tumor-promoting M2 state to the tumor-suppressing M1 phenotype or selectively inhibiting the macrophage-derived factors responsible for mitigating ER stress.

Furthermore, this study emphasizes the nuanced role of the tumor microenvironment in shaping responses to advanced therapies like CAP. While CAP offers a physical and chemical assault on cancer cells, the surrounding stromal and immune cells can actively counteract its effects, highlighting the complexity of tumor ecosystems. Comprehensive profiling of the tumor immune landscape may thus be crucial in predicting and improving patient responses to CAP and other oxidative stress-inducing treatments.

Beyond lung cancer, these insights could be extrapolated to other malignancies where macrophage polarization plays a pivotal role in therapy resistance. The idea that modifying macrophage phenotypes could potentiate CAP efficacy opens a new frontier for immunomodulatory interventions in cancer care. Researchers advocate for further studies to delineate the full spectrum of secreted factors and downstream signaling events mediating this protective effect.

The study utilized sophisticated cellular co-culture systems, flow cytometry, immunoblotting, and gene expression analyses to corroborate their findings, providing a robust experimental framework that marries immunology with plasma medicine. Additionally, animal models confirmed the in vivo relevance, as tumors with increased M2 macrophage content displayed reduced sensitivity to CAP, validating the clinical translatability of the results.

In summary, this pioneering research highlights the vital role of M2 polarized macrophages in orchestrating lung cancer cell survival during cold atmospheric plasma therapy by mitigating ER stress. It underscores the necessity of addressing the tumor microenvironment’s influence to overcome resistance mechanisms effectively. These revelations could inspire the development of combined modalities that integrate CAP with immunomodulatory agents, potentially transforming therapeutic paradigms for lung cancer patients.

As the field of plasma oncology advances, understanding such complex cellular interactions will be paramount to harnessing the full potential of CAP and other emerging treatments. This study serves as a compelling example of how dissecting tumor-immune interactions at the molecular level can unravel hidden mechanisms of resistance and inform innovative therapeutic strategies that ultimately improve patient outcomes.

Subject of Research: The protective role of M2 polarized macrophages in lung cancer cells against cold atmospheric plasma treatment by alleviating endoplasmic reticulum stress.

Article Title: M2 polarization of macrophage protects the lung cancer cells from cold atmospheric plasma via alleviating endoplasmic reticulum stress.

Article References:
Feng, Y., Peng, S., Zhao, L. et al. M2 polarization of macrophage protects the lung cancer cells from cold atmospheric plasma via alleviating endoplasmic reticulum stress. Cell Death Discov. 11, 487 (2025). https://doi.org/10.1038/s41420-025-02775-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02775-4